Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v2-FR | Version v1-EN |
|---|---|---|
| Language | French (Updated) | English |
| Date Updated | 2026-02-09 | 2026-02-09 |
| Drug Identification Number | 02408880 | 02408880 |
| Brand name | MINT-GABAPENTIN | MINT-GABAPENTIN |
| Common or Proper name | Gabapentin | Gabapentin |
| Company Name | MINT PHARMACEUTICALS INC | MINT PHARMACEUTICALS INC |
| Ingredients | GABAPENTIN | GABAPENTIN |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL | ORAL |
| Packaging size | 500 count bottle | 500 count bottle |
| Anatomical Therapeutical Chemical (ATC) code | N02BF | N02BF |
| Anatomical Therapeutical Chemical (ATC) description | ||
| Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | ||
| Actual start date | 2026-02-06 | 2026-02-06 |
| Estimated end date | ||
| Actual end date | 2026-05-30 | 2026-05-30 |
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |